Natco Pharma Limited — Investor Meet, 19-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Natco Pharma reported a consolidated revenue of ₹651.1 crore for Q3 FY25, a decline from ₹795.6 crore in the same quarter last year. The net profit also decreased to ₹132.4 crore compared to ₹212.7 crore the previous year. The lower performance was attributed to no revenues from Revlimid during the quarter and continued high R&D expenses, suggesting a cash flow mismatch.

2. **Future Outlook and Growth Drivers**: Management expressed optimism for future quarters, expecting significant growth from a one-third allocation of Revlimid in FY26. They anticipate that fresh allocations will positively impact the overall performance. Upcoming product launches, notably Semaglutide in India and continued success in the oncology portfolio, are positioned as key growth drivers.

3. **Order Book and Operational Updates**: Significant product launches and approvals are anticipated for FY26, including Everolimus and Risdiplam, which are expected to bolster revenues. Specific details regarding project completion timelines remain confidential.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts raised concerns about revenue projections owing to the absence of Revlimid sales, with management confirming it was the main factor affecting Q3 results. They remain confident about upcoming allocations to improve performance.

- **Market Position and Competitive Landscape**: Analysts questioned Natco’s competitive position regarding Revlimid and other upcoming products; the CEO highlighted that while competition exists, Natco is well-positioned due to its upcoming launches.

- **Operational Challenges or Risks**: Issues surrounding high R&D costs were discussed, with management attributing these to ongoing development projects. There were also queries about potential impacts from U.S. tariffs.

- **Capex and Capital Allocation**: Discussion included the utilization of the company’s cash reserves, with management indicating a strong preference for acquisitions rather than immediate shareholder returns.

- **Strategic Priorities and Long-Term Vision**: Questions about future strategies revealed management's focus on quality product launches and maintaining a robust pipeline, accepting that volatility is inherent in their business model.

5. **Market or Regulatory Updates**: No major regulatory hurdles were reported, but information regarding the ongoing development of Semaglutide and other products was noted, with updates expected in due course.

6. **Strategic Focus Areas**: There is a clear emphasis on expanding the product portfolio, enhancing market reach through strategic acquisitions, and improving operational efficiencies amidst existing market volatility.

7. **Investor Insight**: Given the current financial health and the upcoming product pipeline, there is a potential for future growth despite recent challenges. The emphasis on strategic acquisitions and promising product launches suggests a cautious positive outlook. Monitoring upcoming revenue trends and market developments will be crucial. The current situation may warrant a cautious position.